Emergent Biosolutions
(EBS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2004 | |
| Cash Flows From Operating Activities | |
| Net Income | 11,472 |
| Depreciation Amortization | 1,867 |
| Income taxes - deferred | -418 |
| Accounts receivable | -15,664 |
| Accounts payable and accrued liabilities | 2,472 |
| Other Working Capital | -4,409 |
| Other Operating Activity | 13,876 |
| Operating Cash Flow | $9,196 |
| Cash Flows From Investing Activities | |
| Change In Deposits | 147 |
| PPE Investments | -17,072 |
| Other Investing Activity | -1,250 |
| Investing Cash Flow | $-18,175 |
| Cash Flows From Financing Activities | |
| Change In Short Term Borrowing | 947 |
| Debt Issued | 10,992 |
| Debt Repayment | -2,535 |
| Common Stock Issued | 12 |
| Common Stock Repurchased | -665 |
| Other Financing Activity | -70 |
| Financing Cash Flow | $8,681 |
| Beginning Cash Position | 7,119 |
| End Cash Position | 6,821 |
| Net Cash Flow | $-298 |
| Free Cash Flow | |
| Operating Cash Flow | 9,196 |
| Capital Expenditure | -17,072 |
| Free Cash Flow | -7,876 |